YDES
Yd Bio Ltd Health Care Services-Medical Laboratories Russell 3000
$5.94Close
$420.5MMarket cap
$2.51 – $8.1152-week range
Highlights
Cautions
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
27%
1wk
up 20.0%
price change
1mo
down 19.9%
price change
12-month return
up 137%
total, dividends included
F-score
—
— Not assessed
Altman Z″
-1.35
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
down 1.3%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
up 17%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
—
return on equity
Free cash margin
down 1347%
-$8.0M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
15.2%
$0.90 a day · 2×ATR $4.13
RS
—
vs the universe
Trend
—
trend template
Relative volume
0.1×
vs 50-day average
Up/down volume
1.11
50 sessions
Implied move
—
no scheduled report
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$2.9M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 9.4% over the year, from 65m to 71m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 30.4% to 28.1%. The company is keeping less of each dollar of sales than it did a year ago.
Last shock
Sep 21, 2026-18% in one session1.8× volumeno filing matched+126% since
Financials
- Gross 28%
- Net -1393%
- Free cash -1347%
- Cash
- Long-term debt
| FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|
| Revenue | $350,131 | $510,360 | $596,817 |
| Gross margin | 44% | 30% | 28% |
| Operating income | -$9,847 | -$1.5M | -$5.3M |
| Net income | $13,560 | -$1.4M | -$8.3M |
| Net margin | 4% | -277% | -1393% |
| Earnings per share | $0.00 | -$0.02 | -$0.12 |
| Free cash flow | -$55,947 | -$1.3M | -$8.0M |
| Free cash margin | -16% | -254% | -1347% |
| Cash | $87,098 | $3.1M | $6.0M |
| Long-term debt | — | — | $6,764 |
| Shareholders' equity | $22,994 | $6.6M | -$2.9M |
| Shares outstanding | — | 64.73m | 70.79m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Apr 30, 2026 | Annual ↗ | Dec 31, 2025 | 120d |
| Sep 30, 2025 | Interim ↗ | Jun 30, 2025 | 92d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 1, 2026 | Foreign issuer report ↗ |
| Aug 11, 2026 | Foreign issuer report ↗ |
| May 1, 2026 | Foreign issuer report ↗ |
| Feb 26, 2026 | Foreign issuer report ↗ |
| Jan 30, 2026 | Foreign issuer report ↗ |
| Jan 21, 2026 | Foreign issuer report ↗ |
| Jan 16, 2026 | Foreign issuer report ↗ |
| Jan 15, 2026 | Foreign issuer report ↗ |
| Jan 6, 2026 | Foreign issuer report ↗ |
| Nov 17, 2025 | Foreign issuer report ↗ |
| Sep 30, 2025 | Foreign issuer report ↗ |
| Sep 26, 2025 | Foreign issuer report ↗ |